A prospective cohort study demonstrated that recombinant human ACE2 (rhACE2) efficiently transformed Ang II to Ang (1–7), providing a potential novel treatment for heart failure (Basu et al. 2017; Patel et al. 2017). The gene discussed is AGT; the disease is heart failure.